Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (3,928)	$ (1,429)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation expense	695	175
Fair value adjustment of common stock warrants	(9)	(7)
Depreciation	16	9
Loss on disposal of property and equipment	17	51
Amortization of intangible assets	160	0
Net gain on sale of intangible asset - discontinued operations	0	(2,930)
Provision for doubtful accounts and sales returns allowances - discontinued operations	0	(71)
Tax benefit related to intangibles	(83)	0
Gain on proceeds received from contingent payments - discontinued operations	0	(445)
Change in value of unconsolidated affiliate	0	669
Impairment of unconsolidated affiliate	0	1,377
Changes in operating assets and liabilities:
Accounts receivable	(250)	0
Prepaid expenses and other current assets	(121)	8
Accrued interest on note receivable	(33)	(12)
Accrued interest promissory note	4	0
Accounts payable, accrued expenses and other liabilities	(483)	(64)
Current assets and liabilities from discontinued operations	177	(439)
Net cash used in operating activities	(3,838)	(3,108)
Cash flows from investing activities:
Acquisition of property and equipment - continuing operations	(119)	(4)
Net proceeds received from sale of intangible asset - discontinued operations	0	2,930
Net cash received on OEM asset disposition - discontinued operations	0	502
Net cash, received on SPTS asset disposition - discontinued operations	0	200
Cash received from acquisition	476	0
Issuance of note receivable	(300)	(300)
Net cash provided by investing activities	57	3,328
Cash flows from financing activities:
Net cash used in financing activities	0	0
Effect of exchange rates on cash and cash equivalents	0	25
Net (decrease) increase in cash and cash equivalents	(3,781)	245
Cash and cash equivalents at beginning of year	7,820	7,575
Cash and cash equivalents at end of year	4,039	7,820
Supplemental disclosure of non-cash activities:
Warrants received in exchange for services	75	100
Shares issued in CollabRx acquisition	932	0
Note receivable used as consideration for CollabRx acquisition	300	0
Promissory note issued in CollabRx acquisition	500	0
Fair value of assets acquired	2,253	0
Liabilities assumed in CollabRx acquisition	$ 997	$ 0